Back to search

France· FR:62059315

TELEBRIX GASTRO (300 mg l/mL), solution pour administration par voie orale ou rectale

A medicinal product containing ioxitalamate de méglumine, registered in France by GUERBET, on the national reimbursement list.

Reimbursed in France (Assurance maladie)

Checked against Base de données publique des médicaments — BDPM (France) on

Informational only — not a medical device.

SOURCE REGISTER · FRBase de données publique des médicament…normalisedTELEBRIX GASTRO (300 mg l/mL), soluti…ATC—REGISTER NO.FR:62059315PACKS LISTED2CHECKEDSeptember 12, 2026

The record

At a glance

Base de données publique des médicaments — BDPM (France)
Active substance
IOXITALAMATE DE MÉGLUMINE
Manufacturer
GUERBET
Country
France (FR)
ATC code
—
Reimbursed
Yes
Source register
Base de données publique des médicaments — BDPM (France)
Last checked
September 12, 2026

Packs & prices · 2

2 priced
  • cip13
    3400932748099
    1 flacon(s) en verre de 50 mL
    EUR 5.47
  • cip13
    3400932748150
    1 flacon(s) en verre de 100 mL
    EUR 9.82

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Ioxitalamate de méglumine in 4 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All ioxitalamate de méglumine products

Authorised across Europe · EMA

The same active substance is authorised in 7 EEA countries. Names it is sold under:

  • Belgium · Telebrix Gastro
  • Czechia · Telebrix Gastro
  • Germany · Telebrix Gastro
  • Hungary · Telebrix Gastro
  • Luxembourg · Telebrix Gastro
  • Netherlands · Telebrix Gastro
  • Portugal · Telebrix Gastro

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/db2784b8-1bc4-4d55-b936-9a5b0924d530
GET /v1/drugs/db2784b8-1bc4-4d55-b936-9a5b0924d530?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "cis": "62059315",
  "date_amm": "1985-04-03",
  "type_amm": "Procédure nationale",
  "numero_ue": null,
  "substance": "IOXITALAMATE DE MÉGLUMINE",
  "statut_amm": "Autorisation active",
  "statut_bdm": null,
  "forme_pharmaceutique": "solution ou",
  "voies_administration": "orale;rectale",
  "etat_commercialisation": "Commercialisée",
  "surveillance_renforcee": "Non"
}

See everything about ioxitalamate de méglumine.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.